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Montelukast Pharmacokinetics
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To identify the genetic basis of interindividual variability in montelukast exposure, we determined its pharmacokinetics and
sequenced 379 pharmacokinetic genes in 191 healthy volunteers. An intronic single nucleotide variation (SNV), strongly
linked with UGT1A3*2, associated with reduced area under the plasma concentration–time curve (AUC0-‘) of montelukast
(by 18% per copy of the minor allele; P 5 1.83 3 10210). UGT1A3*2 was associated with increased AUC0-‘ of montelukast
acyl-glucuronide M1 and decreased AUC0-‘ of hydroxymetabolites M5R, M5S, and M6 (P < 1029). Furthermore, SNVs in
SLCO1B1 and ABCC9 were associated with the AUC0-‘ of M1 and M5R, respectively. In addition, a candidate gene analysis
suggested that CYP2C8 and ABCC9 SNVs also affect the AUC0-‘ of montelukast. The found UGT1A3 and ABCC9 variants
associated with increased expression of the respective genes in human liver samples. Montelukast and its hydroxymetabo-
lites were glucuronidated by UGT1A3 in vitro. These results indicate that UGT1A3 plays an important role in montelukast
pharmacokinetics, especially in UGT1A3*2 carriers.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Interindividual variability in the pharmacokinetics of monte-
lukast is high. It is not known how genetic variants in genes
encoding drug-metabolizing enzymes, membrane transporters,
and regulatory proteins contribute to this variability.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study investigated whether genetic variants in pharma-
cokinetic genes affect the pharmacokinetics of montelukast and
its metabolites.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 The results indicate that UGT1A3 plays an important role
in montelukast pharmacokinetics, especially in carriers of the
UGT1A3*2 allele associated with increased UGT1A3 expres-
sion. Furthermore, the results suggest that also CYP2C8 and
ABCC9 variants affect the exposure to montelukast.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Genetic variants explain a significant proportion of interin-
dividual variability in montelukast pharmacokinetics. This
knowledge may aid in individualizing treatment with leukotri-
ene receptor antagonists.
Montelukast is a leukotriene receptor antagonist, which is widely
used in the treatment of asthma.1 After oral administration,
montelukast is extensively metabolized and the majority of
the metabolites are excreted into the bile.2 Previous studies have
shown that the main enzyme involved in the oxidative
metabolism of montelukast is cytochrome P450 (CYP) 2C8.3,4
Also, CYP2C9, CYP3A4, and uridine diphosphate-
glucuronosyltransferase (UGT) 1A3 seem to contribute to the
formation of montelukast metabolites.4–7 Additionally, montelu-
kast has been suggested to be a substrate of organic anion
transporting polypeptide (OATP) 1B1, 1B3, and 2B1
transporters.8–10
High interindividual variability exists in the pharmacokinetics
of montelukast. We hypothesized that variation in genes encod-
ing drug-metabolizing enzymes and membrane transporters, as
well as proteins that affect their expression or biochemistry, con-
tributes to this variability. Therefore, the aim of this study was to
investigate the possible effects of genetic variability in these phar-
macokinetic genes on montelukast pharmacokinetics. To this
end, we determined the pharmacokinetics of montelukast after a
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10-mg dose in 191 healthy volunteers and fully sequenced 379
pharmacokinetic genes using massively parallel sequencing.
RESULTS
Montelukast pharmacogenomics
In the present study, substantial interindividual variability was
observed in the pharmacokinetic variables of montelukast and its
acyl-glucuronide (M1) and hydroxymetabolites (M5R, M5S, and
M6) (Supplementary Table S1). The areas under the plasma
concentration–time curve from 0 h to infinity (AUC0-1) of
montelukast, M1, M5R, M5S, and M6 varied 8.7-fold, 13-fold,
30-fold, 22-fold, and 23-fold between individual subjects,
respectively.
A total of 105,145 single nucleotide variations (SNVs) were
found in the 379 analyzed pharmacokinetic genes (Supplemen-
tary Table S2), of which 46,064 had a minor allele frequency
(MAF) of at least 0.05. In a stepwise linear regression analysis
fixed for demographic covariates, nine common variants (MAF
0.05) in three genes were independently associated with monte-
lukast or its metabolite pharmacokinetics at a Bonferroni-
corrected significance level of 1.09 3 1026 (Table 1). The
AUC0-1 of montelukast and its metabolites showed the stron-
gest associations with variants in the UGT1A gene (Figure 1,
Table 1). For montelukast AUC0-1, the strongest association
was observed with rs7604115, located in the first intron of
UGT1A3. The AUC0-1 of montelukast was 18% smaller per
copy of the variant allele (P5 1.83 3 10210). After adjusting for
this variant, no other variant remained statistically significantly
associated with montelukast AUC0-1. The investigated genetic
variants had no significant effect on the peak plasma concentra-
tion (Cmax) or the elimination half-life (t1=2) of montelukast.
In agreement with the effects of UGT1A variants on parent
montelukast, the AUC0-1 of montelukast acyl-glucuronide (M1)
was 25% larger per copy of the UGT1A rs3806592 variant allele
(P5 6.02 3 1029) (Table 1). Rs3806592 is in a strong linkage
disequilibrium with the UGT1A3 rs7604115 SNV associated
with the AUC0-1 of parent montelukast (r
2 5 0.95, P5 3.65 3
10241). UGT1A variants were also significantly associated with
the Cmax of M1 and the M1/montelukast AUC0-1 ratio. Fur-
thermore, the solute carrier organic anion transporter gene 1B1
(SLCO1B1) SNVs rs73063122 and rs4149056 were significantly
associated with the AUC0-1 and Cmax of M1, respectively. These
two SNVs are in a strong linkage disequilibrium with each other
(r2 5 0.60, P5 5.73 3 10227), suggesting that both of these
associations are due to the rs4149056 missense SNV known to
markedly impair the activity of OATP1B1.11
The effects of UGT1A variants on the AUC0-1 of the hydrox-
ylated M5R, M5S, and M6 metabolites of montelukast were
larger than what was observed for montelukast (Table 1). The
AUC0-1 of M5R, M5S, and M6 were 46% (P5 1.26 3 10
230),
33% (P5 8.14 3 10214), and 39% (P5 2.89 3 10227) smaller
per copy of the rs7604115 variant allele, respectively. UGT1A
variants were also significantly associated with the Cmax and the
metabolite/montelukast AUC0-1 ratios of M5R, M5S, and M6
and the t1=2 of M5R and M5S. The AUC0-1 of M5R was also
associated with the rs704212 SNV in the ATP binding cassette
subfamily C member 9 (ABCC9) transporter gene.
UGT1A linkage disequilibrium and haplotype analyses
The UGT1A gene region (620 kb) was found to consist of nine
linkage disequilibrium (LD) blocks (Figure 1). The SNVs associ-
ated with montelukast or its metabolite pharmacokinetics were
located in blocks 3 and 4. Within these blocks, 28 haplotypes
were inferred (Supplementary Figure S1). The SNVs showing
the strongest associations with montelukast pharmacokinetics
were strongly linked to the missense variants rs3821242 and
rs6431625 (r2  0.69), which together define the UGT1A3*2
haplotype. Based on the missense variants rs3821242, rs6431625,
and rs45449995, the inferred haplotypes were grouped to sub-
types of UGT1A3*1 (wildtype), *2 (rs3821242 and rs6431625;
MAF 0.39), *3 (rs3821242; MAF 0.060), and *6 (rs3821242,
rs6431625, and rs45449995; MAF 0.018). The effects of the
UGT1A3*2 haplotype on montelukast and its metabolite phar-
macokinetics were similar to the effects of the individual, intronic
UGT1A SNVs (Tables 1 and 2, Figure 2).
Functional validation
Next, we investigated whether montelukast or its hydroxymeta-
bolites are substrates of UGT1A enzymes in vitro. As the most
strongly associated variants are localized around the first exon of
UGT1A3, we focused on this enzyme, together with UGT1A1
and UGT1A9, which are also known to catalyze the glucuronida-
tion of carboxylic acids.12 Montelukast, M5R, M5S, and M6
were all metabolized by UGT1A3, but not significantly by
UGT1A1 or UGT1A9 (Supplementary Figure S2).
To further elucidate the mechanisms of associations between
UGT1A, ABCC9, and SLCO1B1 SNVs and montelukast or its
metabolite pharmacokinetics, we then investigated the effects of
the SNVs on the respective gene expression in human liver sam-
ples (Table 3). UGT1A3 expression showed a strong association
with the SNVs associated with montelukast pharmacokinetics.
The strongest association was observed with rs4663969, present
in both UGT1A3*2 and *3 haplotypes. UGT1A3 gene expression
was 24% higher per copy of the variant allele (P5 2.27 3 1024).
Of the UGT1A3*2, *3, and *6 haplotypes, only UGT1A3*2 was
significantly associated with increased UGT1A3 gene expression.
The UGT1A3 expression was 24% higher per copy of the
UGT1A3*2 haplotype (P5 2.08 3 1024) (Figure 3). ABCC9
expression was 25% higher (P5 3.41 3 1024) per copy of the
rs704212 variant allele. SLCO1B1 expression was 13% lower
(P5 0.0146) per copy of the rs4149056 variant allele. Of
SLCO1B1 haplotypes, *15 (rs2306283 and rs4149056) was asso-
ciated with a 15% lower SLCO1B1 expression per copy of the
haplotype (P5 0.00733).
Candidate gene analysis
We next carried out a candidate gene analysis for montelukast
AUC0-1, focusing on common (MAF 0.05) missense variants
in genes suggested to be involved in montelukast pharmacokinet-
ics (CYP2C8, CYP2C9, CYP3A4, SLCO1B1, SLCO1B3,
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SLCO2B1, UGT1A3), as well as the ABCC9 rs704212 SNV
(Supplementary Table S3). In a stepwise linear regression analy-
sis, UGT1A3*2 was associated with a 17% (P5 2.99 3 10210),
ABCC9 rs704212 with a 14% (P5 2.19 3 1024), and
CYP2C8*3 (rs10509681 and rs11572080) with an 11%
(P5 0.00659) reduced, and CYP2C8*4 (rs1058930) with a 13%
(P5 0.0184) increased AUC0-1 of montelukast per copy of each
minor allele (Table 4; adjusted R2 5 0.41).
DISCUSSION
In this study we used targeted massively parallel sequencing of
379 pharmacokinetic genes to characterize the genetic basis of
interindividual variability in montelukast pharmacokinetics. The
UGT1A3*2 haplotype and variants located around the first exon
of UGT1A3 were strongly associated with the systemic exposure
to parent montelukast and its metabolites. We further demon-
strated that montelukast and its hydroxymetabolites are substrates
Table 1 Results of the stepwise forward linear regression analysis of the effects of 46,064 SNVs in 379 genes on montelukast and
its metabolite pharmacokinetics
Pharmacokinetic









AUC0-1 1. rs73063122 SLCO1B1 intron 11/14 c.1497 1 2246A>C 0.32 26.4% 18.5%, 34.8% 9.20 3 10
29
2. rs3806592 UGT1A4 upstream c.-1531C>T 0.40 24.7% 17.4%, 32.3% 6.02 3 1029
Cmax 1. rs3806592 UGT1A4 upstream c.-1531C>T 0.40 30.4% 20.8%, 40.9% 4.45 3 10
28




rs3806592 UGT1A4 upstream c.-1531C>T 0.40 52.9% 43.5%, 63.0% 4.14 3 10222
M5R
AUC0-1 1. rs7604115 UGT1A3 intron 1/4 c.868-17564C>T 0.40 245.7% 249.5%, 241.7% 1.26 3 10
230
2. rs704212 ABCC9 intron 12/37 c.1802 1 2622G>A 0.14 227.6% 234.6%, 219.8% 4.83 3 1027
Cmax rs7604115 UGT1A3 intron 1/4 c.868-17564C>T 0.40 233.9% 238.6%, 228.8% 7.13 3 10
217




rs4663969 UGT1A3 intron 1/4 c.867 1 16674C>A 0.46 233.9% 237.3%, 230.2% 7.06 3 10227
M5S
AUC0-1 rs7604115 UGT1A3 intron 1/4 c.868-17564C>T 0.40 233.2% 238.5%, 227.5% 8.14 3 10
214
Cmax rs7604115 UGT1A3 intron 1/4 c.868-17564C>T 0.40 226.2% 231.2%, 220.8% 1.82 3 10
211




rs2361501 UGT1A3 intron 1/4 c.867 1 51A>T 0.47 220.1% 224.7%, 215.3% 1.71 3 1029
M6
AUC0-1 rs7604115 UGT1A3 intron 1/4 c.868-17564C>T 0.40 239.4% 243.2%, 235.4% 2.89 3 10
227





rs4663969 UGT1A3 intron 1/4 c.867 1 16674C>A 0.46 225.4% 228.1%, 222.7% 2.77 3 10229
AUC0-1, area under the plasma concentration-time curve from 0 h to infinity; CI, confidence interval; Cmax, peak plasma concentration; dbSNP, National Center for Biotech-
nology Information Short Genetic Variations database; MAF, minor allele frequency; SNV, single nucleotide variation; t1=2, elimination half-life.
aPer copy of the minor allele.
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of UGT1A3 in vitro and that the variants associated with the
pharmacokinetic variables also significantly affect UGT1A3 gene
expression in human liver. In addition, our results indicate involve-
ment of ABCC9 and SLCO1B1 in the pharmacokinetics of mon-
telukast metabolites. Moreover, a candidate gene approach
suggested that, in addition to UGT1A3 variants, also CYP2C8 and
ABCC9 variants affect parent montelukast exposure.
The UGT1A gene encodes the UGT1A family enzymes, which
catalyze the formation of hydrophilic glucuronide metabolites.13
Individual UGT1A genes have unique first exons but share exons
2–5. Strong linkage disequilibrium exists throughout the whole
UGT1A gene (Figure 1c). The intronic UGT1A SNVs showing
the strongest associations with montelukast or its metabolite
pharmacokinetics are strongly linked to the UGT1A3 missense
Figure 1 The associations of SNVs in 379 pharmacokinetic genes (a) and in the UGT1A gene (b) with montelukast AUC0-1, and LD plot of the UGT1A
gene (c). The Y-axes in (a,b) describe the negative logarithm of the P value for each SNV and the horizontal lines indicate the Bonferroni-corrected signifi-
cance level of 1.09 3 1026. The X-axis in (a) shows individual SNVs grouped by protein function. The locations of UGT1A exons and linkage disequilibrium
blocks are depicted on the top of (b,c).
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variants rs3821242 (c.31T>C, p.Trp11Arg) and rs6431625
(c.140T>C, p.Val47Ala) that together define the haplotype
UGT1A3*2. The UGT1A3*2 haplotype and the individual
intronic SNVs similarly reduced the exposure to montelukast and
its hydroxymetabolites, and increased the exposure to montelu-
kast acyl-glucuronide, indicating enhanced glucuronidation. Con-
sistently, UGT1A3*2 has previously been shown to increase the
metabolism of the UGT1A3 substrates atorvastatin, telmisartan,
and febuxostat in humans.14–16
The UGT1A3*2 haplotype and the UGT1A SNVs associated
with montelukast pharmacokinetics significantly increased
UGT1A3 mRNA expression in human liver samples. Similarly, a
previous study also showed that UGT1A3 mRNA and protein
expression are significantly increased in UGT1A3*2 carriers.14 In
addition to UGT1A3*2, the UGT1A3*6 haplotype has been asso-
ciated with increased UGT1A3 expression.14 In our study, the
number of UGT1A3*6 carriers was relatively small, and only a
tendency towards increased UGT1A3 expression could be
observed (Figure 3).
The causal variant of UGT1A3*2 affecting UGT1A3 expres-
sion has remained unknown.14 We identified several intronic
SNVs that are strongly linked to UGT1A3*2 (Supplementary
Table 2 Results of the stepwise forward linear regression analysis of the effects of UGT1A3*2, SLCO1B1 rs4149056, and ABCC9
rs704212 on montelukast and its metabolite pharmacokinetics
Pharmacokinetic variable Haplotype/dpSNP ID
Effecta
Average 90% CI P value
Montelukast





AUC0-1 UGT1A3*2 26.4% 19.2%, 34.1% 5.13 3 10
210
SLCO1B1 rs4149056 34.4% 24.8%, 44.8% 5.20 3 10210
Cmax UGT1A3*2 30.0% 20.4%, 40.5% 6.71 3 10
28
SLCO1B1 rs4149056 35.5% 22.9%, 49.4% 6.54 3 1027
t1/2 —
M1/montelukast AUC0-1 ratio UGT1A3*2 52.8% 43.3%, 62.8% 5.82 3 10
222
M5R
AUC0-1 UGT1A3*2 245.4% 249.2%, 241.2% 1.20 3 10
229
ABCC9 rs704212 227.6% 234.8%, 219.7% 6.90 3 1027
Cmax UGT1A3*2 233.8% 238.5%, 228.7% 7.49 3 10
217
t1/2 UGT1A3*2 225.3% 228.9%, 221.6% 1.26 3 10
218
M5R/montelukast AUC0-1 ratio UGT1A3*2 235.0% 238.6%, 231.2% 1.01 3 10
226
M5S
AUC0-1 UGT1A3*2 233.1% 238.4%, 227.4% 9.01 3 10
214
Cmax UGT1A3*2 226.0% 231.0%, 220.6% 2.65 3 10
211
t1/2 UGT1A3*2 221.8% 227.1%, 216.1% 2.79 3 10
28
M5S/montelukast AUC0-1 ratio UGT1A3*2 218.9% 223.8%, 213.8% 5.87 3 10
28
M6
AUC0-1 UGT1A3*2 239.3% 243.1%, 235.2% 3.41 3 10
227
Cmax UGT1A3*2 233.9% 237.7%, 229.8% 2.65 3 10
223
t1/2 —
M6/montelukast AUC0-1 ratio UGT1A3*2 226.1% 228.9%, 223.1% 3.56 3 10
227
AUC0-1, area under the plasma concentration-time curve from 0 h to infinity; CI, confidence interval; Cmax, peak plasma concentration; dbSNP, National Center for Biotech-
nology Information Short Genetic Variations database; t1=2, elimination half-life.
aPer copy of the minor allele.
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Figure S1). Of these, rs3806597 (c.-204A>G) is located on a
proposed farnesoid X receptor (FXR) binding site upstream of
UGT1A3, but the variant allele has not affected FXR-mediated
induction of UGT1A3 by the bile acid chenodeoxycholic acid.17
None of the other strongly linked variants appear to be located
in a transcription factor binding site upstream of UGT1A3.18 In
addition to being associated with expression, the UGT1A3*2 mis-
sense variants might also alter the enzymatic activity of
UGT1A3. However, in vitro studies with these variants have
shown conflicting results, with reduced, increased, and
unchanged activity.19–21 Altogether, although the causal variant
cannot be identified, the increased UGT1A3 expression in associ-
ation with UGT1A3*2 provides a mechanistic explanation for
our pharmacokinetic results.
In accordance with a recently published in vitro study,7 our results
demonstrate that montelukast is efficiently glucuronidated by
UGT1A3. We also showed that montelukast hydroxymetabolites
M5R, M5S, and M6 are efficiently glucuronidated by UGT1A3 in
vitro, which could explain why the concentrations of the hydroxy-
metabolites were affected more by the UGT1A3 variants than those
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Figure 2 Geometric mean (90% CI) plasma concentrations of montelukast, its acyl-glucuronide (M1), and hydroxymetabolites (M5R, M5S, M6) after a
single 10-mg oral dose of montelukast in 191 healthy volunteers with different UGT1A3 genotypes. Open circles indicate noncarriers of UGT1A3*2
(n 5 72), solid circles subjects heterozygous for the UGT1A3*2 (n 5 90), and solid triangles subjects homozygous for the UGT1A3*2 haplotype (n 5 29).
The insets depict the same data on a semilogarithmic scale. Plasma concentrations of montelukast were adjusted for BSA and those of M1 and M5S for
lean body weight, as according to the linear regression models of their AUC0-1 values.
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of parent montelukast. Taken together, our results indicate that glu-
curonidation plays an important role in the metabolism of both par-
ent montelukast and its hydroxymetabolites. However, due to low
plasma concentrations, the hydroxymetabolites are unlikely to con-
tribute to the pharmacological effects of montelukast.
In addition to UGT1A3 variants, SNVs in the SLCO1B1 gene
were associated with significantly higher AUC and Cmax
of montelukast acyl-glucuronide, M1. SLCO1B1 encodes
OATP1B1, an influx transporter mediating the hepatic uptake of
its substrates from sinusoidal blood.11 Of the associated SNVs,
Table 3 Results of the linear regression analysis of the effects of UGT1A SNVs and haplotypes on UGT1A3 mRNA expression, ABCC9
rs704212 SNV on ABCC9 mRNA expression, and SLCO1B1 SNVs and haplotypes on SLCO1B1 mRNA expression in liver samples
from patients undergoing laparoscopic gastric bypass operation
Gene n dpSNP ID/Haplotype
MAF Effecta
P value(n 5 185-197) Average 90% CI
UGT1A3 136 rs7604115 0.44 22.3% 11.3%, 34.5% 5.65 3 1024
136 rs3806592 0.43 22.9% 11.7%, 35.2% 4.78 3 1024
136 rs7556676 0.47 23.2% 12.4%, 35.0% 2.57 3 1024
136 rs4663969 0.47 23.6% 12.7%, 35.6% 2.27 3 1024
136 rs1875263 0.44 22.9% 11.7%, 35.2% 4.78 3 1024
136 UGT1A3*2 0.41 23.8% 12.8%, 35.8% 2.08 3 1024
136 UGT1A3*3 0.058 21.2% 218.7%, 20.0% 0.918
136 UGT1A3*6 0.010 29.9% 213.3%, 94.7% 0.286
ABCC9 187 rs704212 0.11 25.2% 13.1%, 38.6% 3.41 3 1024
SLCO1B1 124 rs4149056 0.24 213.5% 221.4%, 24.7% 0.0146
124 rs2306283 0.47 27.5% 214.7%, 0.4% 0.117
123 SLCO1B1*1B 0.18 10.4% 0.8%, 20.9% 0.0740
123 SLCO1B1*5 0.019 11.2% 218.3%, 51.3% 0.570
123 SLCO1B1*15 0.22 215.2% 223.2%, 26.3% 0.00733
MAF, minor allele frequency.
aPer copy of the minor allele.
Figure 3 Boxplots of the effects of UGT1A3*2, *3, and *6 haplotypes on UGT1A3 mRNA expression in human liver samples. The horizontal lines inside
the boxes represent the median, the box edges show the lower and upper quartiles, and the whiskers show the 10th and 90th percentiles. Individual data
points are given as circles for men and as triangles for women.
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the rs4149056 missense variant (c.521T>C, p.Val174Ala,
SLCO1B1*5 or *15) markedly impairs the function of
OATP1B1, as demonstrated both in vitro and in vivo in
humans.11,22–24 Many glucuronide conjugates are OATP1B1
substrates and our results suggest that also M1 is a substrate of
OATP1B1. In a previous study, the rs2306283 (c.388A>G,
p.Asn130Asp) missense variant was associated with increased
SLCO1B1 expression in human liver samples (n5 143), whereas
rs4149056 had no effect.25 In our study, however, rs4149056 was
associated with decreased SLCO1B1 expression, but rs2306283
appeared to have no effect. Nevertheless, the SLCO1B1*1B hap-
lotype, which contains rs2306283 without rs4149056, showed a
tendency for a 10% increased expression of SLCO1B1 per copy
of the haplotype.
A recent study suggested that montelukast is a substrate of
OATP1B1, 1B3, and 2B1, and that OATP-CYP2C8 interplay is
an important determinant of parent montelukast pharmacokinet-
ics.10 Our finding that the OATP1B1 function-impairing
rs4149056 SNV did not significantly affect the pharmacokinetics
of parent montelukast, even in the candidate gene analysis with
no correction for multiple testing, indicates that OATP1B1 is
not of major importance for the hepatic elimination of montelu-
kast in vivo in humans. Moreover, we fully sequenced the
SLCO1B3 and SLCO2B1 genes and found no association
between montelukast AUC and variants in these genes, indicat-
ing that these genes are also not important determinants of inter-
individual variability in montelukast pharmacokinetics.
Interestingly, the ABCC9 rs704212 SNV was associated with
reduced plasma concentrations of montelukast hydroxymetabo-
lite M5R, and with increased mRNA expression of ABCC9 in
human liver samples. Based on these results, the SNV was
selected for the candidate gene analysis, where it was found to be
associated also with reduced AUC of montelukast. The ABCC9
gene encodes the sulfonylurea receptor 2 (SUR2), which is a sub-
unit of an adenosine triphosphate-sensitive K1 channel and has
no identified transporter function.26 Notably, another ABCC9
SNV, rs1283807, which is in a strong linkage disequilibrium with
rs704212 (r2 5 0.82, P5 1.97 3 10237), has previously been
associated with impaired efficacy of angiotensin II receptor antag-
onists in a genome-wide association study.27 The same SNV has
also been associated with the risk of virologic failure during
efavirenz-containing antiretroviral therapy via an epistatic inter-
action with an SNV in transporter 1, ATP-binding cassette
subfamily B member (TAP1).28 Our study is the first to show an
association between ABCC9 and drug pharmacokinetics, sugges-
ting a pharmacokinetic explanation also for the findings concern-
ing angiotensin II receptor antagonists and efavirenz.
It has been estimated that 80% of montelukast metabolism is
mediated by CYP2C8.6 In the analysis of all the 379 genes,
CYP2C8 variants were not significantly associated with montelu-
kast pharmacokinetics. However, in the candidate gene analysis,
the AUC of montelukast was reduced by the CYP2C8*3 allele
and increased by the CYP2C8*4 allele. These findings are consis-
tent with previous studies indicating increased CYP2C8 activity
with CYP2C8*3 and reduced activity with CYP2C8*4 in vivo in
humans.29–35 In the present study, UGT1A3*2 reduced the
AUC of montelukast by 18% per allele copy, equivalent to a 22%
increase in oral clearance. The simultaneous increase in the M1/
montelukast AUC ratio suggests an about 50% increase in
UGT1A3-mediated clearance per UGT1A3*2 allele. Thus, it
seems plausible that the contribution of UGT1A3 to the metab-
olism of montelukast varies between 35–60%, depending on the
UGT1A3 genotype. In previous studies, the CYP2C8 inhibitor
gemfibrozil has markedly increased the AUC of montelukast.3,6
Interestingly, gemfibrozil inhibits UGT1A3 in vitro.7 Therefore,
it is possible that UGT1A3 also contributes to the gemfibrozil-
montelukast interaction. In any case, the UGT1A3 genotype
might affect the magnitude of this interaction.
Considerable interindividual variability exists in the efficacy of
montelukast, but no firm clinical or genetic predictors of monte-
lukast response have yet been identified.36,37 In clinical practice,
montelukast is administered on a regular basis. The steady-state
plasma concentrations for montelukast are predictable from its
pharmacokinetic parameters measured after a single dose.38
Therefore, the effects of genetic variants on the steady-state
plasma concentrations of montelukast should be similar to the
effects on the AUC0-1 of montelukast observed in our study
after a single dose. Because montelukast dose-dependently
improves chronic asthma,39 the reduced plasma concentrations of
montelukast due to the UGT1A3*2 haplotype might impair its
efficacy. Even though the effect of the UGT1A3*2 haplotype on
montelukast pharmacokinetics is modest, the haplotype is com-
mon (Supplementary Figure S3). Therefore, it may be an
important factor explaining the variability in montelukast
response at the population level. Body surface area and the
UGT1A3*2 allele together explained 32% of interindividual
Table 4 Results of the candidate gene analysis on montelukast AUC0-1
Variable MAF
Effecta
P value Adjusted R2 for each stepAverage 90% CI
BSA — 211.5% 214.0%, 29.0% 2.10 3 10211 0.17
UGT1A3*2 0.39 216.8% 220.5%, 212.9% 2.99 3 10210 0.32
ABCC9 rs704212 0.14 213.7% 219.1%, 27.9% 2.19 3 1024 0.37
CYP2C8*3 0.11 211.3% 217.5%, 24.7% 0.00659 0.40
CYP2C8*4 0.07 12.7% 3.7%, 22.5% 0.0184 0.41
BSA, body surface area; AUC0-1, area under the plasma concentration-time curve from 0 h to infinity; CI, confidence interval; MAF, minor allele frequency.
aBSA effect per 10% increase; genetic variant effect per copy of the minor allele.
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variability in montelukast exposure. When the ABCC9 and
CYP2C8 alleles were added to the model, this percentage
increased to 41%. Together with pharmacodynamic markers,37
this knowledge might aid in individualizing treatment with leu-
kotriene receptor antagonists.
In conclusion, genetic variability in UGT1A3 significantly
affects montelukast pharmacokinetics. This indicates that glucur-
onidation via UGT1A3 has a larger role in the metabolism of
montelukast than previously thought, especially in subjects carry-
ing the UGT1A3*2 haplotype. These results also further confirm
that the UGT1A3*2 haplotype enhances the glucuronidation of
UGT1A3 substrates. Moreover, the candidate gene analysis sug-
gested that also CYP2C8*3, CYP2C8*4, and ABCC9 rs704212
affect the pharmacokinetics of montelukast.
METHODS
Study participants
In all, 201 healthy unrelated Finnish Caucasian volunteers participated
in the pharmacokinetic study after giving written informed consent.
Their health was confirmed by medical history, clinical examination, and
laboratory tests. Participants were not on any continuous medication
nor were tobacco smokers. The study was approved by the Coordinating
Ethics Committee of the Hospital District of Helsinki and Uusimaa and
the Finnish Medicines Agency Fimea. Ten participants discontinued the
study before montelukast administration and thus the pharmacokinetic
data were obtained from 191 participants. Of these, 92 were women and
99 men. Their mean 6 SD age was 24 6 4 years, height 174 6 9 cm,
weight 70 6 12 kg, and body mass index (BMI) 22.8 6 2.5 kg/m2.
A whole-blood DNA sample and a liver biopsy were obtained from
201 patients undergoing laparoscopic gastric bypass operation at the
Kuopio University Hospital, as part of the Kuopio Obesity Surgery
Study.40–42 Good quality RNA expression data and genotypes were
obtained from 188 patients. These patients consisted of 129 women and
59 men (mean 6 SD: age 48 6 9 years and BMI 44 6 6 kg/m2).
Seventy-six patients had type 2 diabetes, 34 had nonalcoholic fatty liver,
32 had nonalcoholic steatohepatitis, and 58 used lipid-lowering medica-
tion. The degree of liver steatosis was graded from 0 to 3 and that of lob-
ular inflammation from 0 to 2. Written informed consent was obtained
from all patients and the study protocol was approved by the Ethics
Committee of the Northern Savo Hospital District.
Montelukast pharmacokinetics
After fasting overnight, the healthy volunteers ingested a single 10-mg
dose of montelukast (Singulair tablet, Merck Sharp & Dohme, Haarlem,
The Netherlands) with 150ml of water at 8 AM. Standardized meals
were served at 4, 7, and 10 h after montelukast ingestion. Timed blood
samples (4–9ml each) were collected into light-protected ethylenediami-
netetraacetic acid (EDTA) tubes prior to and up to 24 h after montelu-
kast administration. Tubes were immediately placed on ice and plasma
was separated within 30min. Samples were stored at –708C until
analysis.
The concentrations of plasma montelukast, montelukast acyl-
glucuronide (M1), montelukast 1,2-diol (M6), 21R-hydroxy montelukast
(M5R), and 21S-hydroxy montelukast (M5S) were measured using a
Nexera X2 liquid chromatography instrument (Shimadzu, Kyoto, Japan)
interfaced with a 5500 Qtrap tandem mass spectrometer (AB Sciex,
Toronto, ON). Prior to quantification, the plasma sample was purified
from proteins and phospholipids using a Phree phospholipid removal
plate (Phenomenex, Torrance, CA) according to the manufacturer’s
instructions. In short, the plasma sample was mixed with acetonitrile
containing 1% formic acid and internal standards (1:4 v/v) and drawn
through the Phree cartridges. The chromatographic separation was
achieved on a reversed-phase Kinetex C18 analytical column (100 3
2.1mm internal diameter, 2.6 lm particle size; Phenomenex) using
2mM ammonium acetate (A) (pH 4.0) adjusted with 98% formic acid
and acetonitrile (B) as a mobile phase. The injection volume was 3 ll and
the column temperature was held at 308C. The gradient profile was set
as follows: a linear increase from 35% B to 62% B over 2.2min, held at
62% B for 2min, a gradient from 62% B to 95% B over 0.6min, and
maintained at 95% B for 1.4min followed by a reversion to the initial
conditions. The mass spectrometer was operated in a positive electro-
spray ionization mode (ESI1) employing scheduled multiple reaction
monitoring (MRM) for the optimal dwell time for each analyte. A corre-
sponding deuterated reference compound served as internal standard for
each analyte, except for M6, which utilized montelukast-d6. The target
mass-to-charge ratios (m/z) for montelukast, M1, M5R/M5S, and M6
were 586!422, 762!422, 602!147, and 602!438, and the limits of
quantification (ng/ml) were 1.0, 0.2, 0.1, and 0.1, respectively. The day-
to-day coefficient of variation (CV) was below 10% at relevant concen-
trations for all analytes. The AUC0-1, Cmax, and t1=2 values were
calculated for montelukast, M1, M5R, M5S, and M6 with standard non-
compartmental methods using Phoenix WinNonlin, v. 6.3 (Certara,
Princeton, NJ).
DNA sequencing and genotyping
Genomic DNA was extracted using the Maxwell 16 LEV Blood DNA
Kit on a Maxwell 16 Research automated nucleic acid extraction system
(Promega, Madison, WI; pharmacokinetic study) or DNeasy Blood &
Tissue Kit (Qiagen, Hilden, Germany; liver samples). DNA concentra-
tion and absorbance 260/280 ratio (A260/A280) were determined with
the NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scien-
tific, Waltham, MA).
Targeted massively parallel sequencing of the 379 pharmacokinetic
genes 620 kb (Supplementary Table S2; genome build GRCh37) was
performed in all pharmacokinetic study participants (n5 201). For
library preparation, 3 lg of genomic DNA was processed according to
the NEBNext DNA Sample Prep protocol (New England BioLabs, Ips-
wich, MA). Target enrichment capture was performed using the Nimble-
Gen SeqCap EZ Choice capture protocol (Roche Sequencing,
Pleasanton, CA). Sequencing was done on the Illumina HiSeq2000 plat-
form with 100 bp paired-end reads (Illumina, San Diego, CA). Quality
control, short read alignment, and variant calling and annotation were
carried out using an in-house-developed pipeline, as described previ-
ously.43 The sequencing and bioinformatics pipelines were carried out at
the Technology Centre at the Institute for Molecular Medicine Finland
(Helsinki, Finland). Mean coverage depth was 37.23. Coverage depth
103, Hardy–Weinberg equilibrium P < 3.15 3 1027 (Bonferroni-
correction), and proportion missing 0.05 were employed as quality
thresholds for including genotype data in statistical analysis.
The pharmacokinetic study participants and liver samples were geno-
typed for the UGT1A rs7604115, rs3806592, rs7556676, rs4663969,
rs1875263, rs3821242, rs6431625, and rs45449995, ABCC9 rs704212,
and SLCO1B1 rs4149056 and rs2306283 SNVs with TaqMan genotyp-
ing assays on a QuantStudio 12K Flex Real-Time PCR System according
to the manufacturer’s protocol (Thermo Fisher Scientific). Call identity
with sequencing data was 99–100%. In case of discordant results, geno-
types obtained by sequencing were used in the statistical analysis.
Reverse transcription quantitative real-time PCR
RNA from liver samples was extracted using the miRNeasy Mini Kit
(Qiagen, Chatsworth, CA) and stored at –808C. RNA was reverse-
transcribed using the SuperScript VILO cDNA Synthesis Kit, according
to the manufacturer’s instructions (Thermo Fisher Scientific). The
cDNA samples were preamplified (14 cycles) with a custom TaqMan
pre amp pool containing the assays for UGT1A, ABCC9, SLCO1B1 and
reference genes before quantitative real-time PCR (qPCR), according to
the manufacturer’s instructions (Thermo Fisher Scientific).
The qPCR was carried out using OpenArray technology on the Quant-
Studio 12K Flex Real-Time PCR System. The custom OpenArray plate
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contained UGT1A3 (Hs04194492_g1), ABCC9 (Hs00245832_m1),
SLCO1B1 (Hs00272374_m1), and reference gene assays, allowing the
within-sample normalization with multiple reference genes. The reference
genes were comprised of actin beta (ACTB; Hs01060665_g1), ribosomal
protein lateral stalk subunit P0 (RPLP0; Hs99999902_m1),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs02758991_g1),
and beta-2-microglobulin (B2M; Hs00984230_m1). Prior to thermal
cycling, a volume of 2.5 lL of TaqMan OpenArray Real-Time PCR Mas-
ter Mix (Thermo Fisher Scientific) was combined with 1.3 lL nuclease-
free water followed by 1.2 lL of cDNA, and the sample was loaded to
OpenArray plate. The samples were processed on the Freedom EVO 150
automated liquid handling system (Tecan Group, M€annedorf, Switzer-
land) and the OpenArray AccuFill instrument (Thermo Fisher Scientific).
Data were analyzed with the ExpressionSuite software (v. 1.0.3, Thermo
Fisher Scientific) using the comparative DCq method.
In vitro studies with UGT1A1, 1A3, and 1A9 recombinant
enzymes
The incubation mixtures (triplicate samples) contained 100mM phos-
phate buffer, pH 7.4, 5mM MgCl2, 0.3mg/ml of supersomal protein
(Corning, Woburn, MA), 2mM UDP-glucuronic acid (UDPGA, triam-
monium salt), and 0.1 lM montelukast, M5R, M5S, or M6, in a total
volume of 500 ll. Control incubations (duplicate samples) were per-
formed with control supersomes, which do not contain active UGT
enzyme. The reactions were initiated by the addition of the substrate
and incubated in a shaking water bath at 378C. Reactions were stopped
by moving 50 ll samples to 50 ll acetonitrile containing 1% formic acid
and internal standards at timepoints 0, 6, 12, 20, 40, and 60min. After
centrifugation, the supernatants were analyzed using SCIEX API 2000
tandem mass spectrometer (AB Sciex), as described previously.4 Deple-
tion (% remaining) of the substrates at each timepoint was calculated for
UGT1A1, 1A3, 1A9, and control samples.
Statistical analysis
The data were analyzed with the statistical programs JMP Genomics 7.0
(SAS Institute, Cary, NC) and IBM SPSS 22.0 for Windows (Armonk,
NY). The pharmacokinetic variables were logarithmically transformed
before analysis.44 Possible effects of demographic covariates on pharmaco-
kinetic variables and gene expression were investigated using stepwise lin-
ear regression analysis, with P-value thresholds of 0.05 for entry and 0.10
for removal. Sex, body weight, lean body weight,45 and body surface area,
(BSA)46 were tested as demographic covariates for pharmacokinetic data,
and age, sex, BMI, type 2 diabetes, degree of lobular inflammation and
hepatic steatosis, and use of lipid-lowering medication for gene expression
data (Supplementary Table S4). Possible effects of genetic variants on
pharmacokinetic variables were investigated using stepwise linear regres-
sion analysis fixed for significant demographic covariates. A Bonferroni-
corrected P-value threshold of 1.09 3 1026 was employed for the 379
gene and UGT1A3 haplotype-based analysis and thresholds of 0.05 for
entry and 0.10 for removal for the candidate gene analysis. The effects of
genetic variants on gene expression were investigated with linear regression
analysis fixed for significant demographic covariates, with P < 0.05 consid-
ered statistically significant. Additive coding was employed for genetic var-
iants and multiallelic variants were expanded. The LD blocks for UGT1A
(620 kb) SNVs (MAF >0.05) were created using a previously described
algorithm,47,48 as implemented in JMP Genomics. Haplotype computa-
tions were performed with PHASE v. 2.1.1.49,50
Additional Supporting Information may be found in the online version of
this article.
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